[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-353369-105":59,"doc-detail-353369-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","sez6-targeting-antibody-drug-conjugate-abbv-706-in-advanced-small-cell-lung-cancer-and-solid-tumors-a-phase-1-trial","SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors - a phase 1 trial","","A phase 1, open-label trial evaluated ABBV-706, a SEZ6-directed antibody-drug conjugate carrying a topoisomerase-1 inhibitor, administered intravenously every 3 weeks to 288 patients with advanced solid tumors, including 124 with relapsed/refractory small cell lung cancer. Safety and tolerability endpoints assessed anemia and fatigue as common treatment-related adverse events, with grade ≥3 events dose-dependent. Antitumor activity showed an objective response rate of 52% in R/R SCLC, with higher durability at 1.8 mg/kg. Overall survival was highest at 1.8 mg/kg, leading to confirmation of 1.8 mg/kg Q3W as the recommended phase 2 dose.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/sez6-targeting-antibody-drug-conjugate-abbv-706-in-advanced-small-cell-lung-cancer-and-solid-tumors-a-phase-1-trial/353369/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/sez6-targeting-antibody-drug-conjugate-abbv-706-in-advanced-small-cell-lung-cancer-and-solid-tumors-a-phase-1-trial/353369.png","ImageObject",300,407,{"name":92,"@type":93},"OmBimo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-19","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is ABBV-706 and what target does it use?","Question",{"text":112,"@type":113},"ABBV-706 is a SEZ6-targeting antibody-drug conjugate. It links a SEZ6-directed antibody to a topoisomerase-1 inhibitor that induces DNA damage after internalization.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How often was ABBV-706 administered in the trial?",{"text":117,"@type":113},"ABBV-706 was given intravenously every 3 weeks (Q3W) in the phase 1 study.",{"name":119,"@type":110,"acceptedAnswer":120},"What dose was confirmed as the recommended phase 2 dose for R/RSCLC?",{"text":121,"@type":113},"The optimal RP2D was confirmed as 1.8 mg/kg Q3W for patients with R/RSCLC, based on safety, preliminary efficacy measures, and pharmacokinetics.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},353369,1790256785,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962090893581,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","nature medicine  \nArticle [https://doi.org/10.1038/s41591-026-04452-0](https://doi.org/10.1038/s41591-026-04452-0)  \nSEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial  \n\n| Received: 20 April 2026\u003Cbr>Accepted: 7 May 2026\u003Cbr>Published online: 1 June 2026  Check for updates | A list of authors and their affiliations appears atthe end of the paper\u003Cbr>Seizure-related homolog 6 (SEZ6) is expressed in small cell lung cancer (SCLC) and neuroendocrine neoplasms. Inan open label, phase 1 trial, ABBV-706, an antibody−drug conjugate with aSEZ6-directed antibody linked to topoisomerase-1 inhibitor (Top1i), was administered intravenously every 3 weeks (Q3W) to 288 patients with advanced solid tumors; 240 received monotherapy, including 124 with relapsed/refractory (R/R) SCLC. Primary objectives of dose escalation (part 1, advanced solid tumors), dose optimization and expansion (part 2, R/RSCLC only) and dose expansion (part 4, central nervous system tumorsand high-grade neuroendocrine neoplasms only) were to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 monotherapy and, from parts 1 and 2, to determine the recommended phase 2 dose (RP2D) of ABBV-706 inR/RSCLC. In themonotherapy cohort (N = 240), the most common treatment-related adverse events (TRAEs) at any grade were anemia (61%) and fatigue (38%). Grade 3 or higher TRAEs occurred in 61% of patients and were dose dependent (39% at 1.8 mg kg−1 and 70% at 2.5 mg kg−1). IntheR/RSCLC monotherapy cohort (n = 124), any-grade and grade 3 or higher TRAEs occurred in 93% and 61% of patients, respectively. ABBV-706 demonstrated promising preliminary efficacy inpatients with R/RSCLC, with an objective response rate (ORR) of 52%(65/124). Inpatients with R/RSCLC receiving monotherapy indose optimization and expansion part 2, ORR was similar between 1.8 mg kg−1 and 2.5 mg kg−1 doses (56%(23/41) and 59%(23/39), respectively), with a duration of response that was highest atthe 1.8 mg kg−1 dose and with most patients achieving rapid and durable tumor reduction. Although exploratory, long-term efficacy measures were an important consideration in the RP2D determination, and inR/RSCLC monotherapy, overall survival (OS) was highest atthe 1.8 mg kg−1 dose, with a median OS of 12.4 months. Based on the totality of available data, including, but not limited to, safety, preliminary efficacy measures and PK, 1.8 mg kg−1 Q3W was confirmed asthe optimal RP2D for patients with R/RSCLC.\u003Cbr>[ClinicalTrials.gov:](ClinicalTrials.gov: NCT05599984)[ NCT05599984](ClinicalTrials.gov: NCT05599984). |\n| --- | --- |\n| e-mail: [lbyers@mdanderson.org](lbyers@mdanderson.org) |  |\n\nNature Medicine | Volume 32 | August 2026 | 2898–2908 2898  \nSmall cell lung cancer (SCLC) accounts for about 11% of all lung cancers1 and isan aggressive neuroendocrine carcinoma characterized by rapid proliferation and early metastatic spread2. Most patients (69%) are diagnosed with extensive-stage disease1. Although most patients with SCLCinitially respond to chemotherapy (with or without immunotherapy), relapse after first-line therapy is common, with nearly 50% of patients experiencing disease progression within 6 months and only approximately 10% remaining disease free after 2 years3,4. For patients with extensive-stage SCLC, the 5-year overall survival (OS) rate is only approximately 12%4. In the IMpower133 and CASPIAN trials, the addition of immune checkpoint inhibitors to platinum-etoposide chemotherapy modestly improved median OS to 12.3 months and 13.0 months, respectively, compared to 10.3 months with chemotherapy alone5,6. However, only approximately 15–23% of patients who responded to treatment had ongoing responsesat 12 months, highlighting the limited durability of benefit5,6. These outcomes reinforce the unmet need for novel therapies with improvedefficacyandtolerability for patients with extensive-stageSCLC.  ","cbCainAU6JsJJhbO","https://ap.wps.com/l/cbCainAU6JsJJhbO","pdf",3990760,28,"English","# Overview\n## Trial design and objectives\n## Safety and tolerability\n## Pharmacokinetics and immunogenicity\n## Antitumor efficacy and RP2D","[{\"question\":\"What is ABBV-706 and what target does it use?\",\"answer\":\"ABBV-706 is a SEZ6-targeting antibody-drug conjugate. It links a SEZ6-directed antibody to a topoisomerase-1 inhibitor that induces DNA damage after internalization.\"},{\"question\":\"How often was ABBV-706 administered in the trial?\",\"answer\":\"ABBV-706 was given intravenously every 3 weeks (Q3W) in the phase 1 study.\"},{\"question\":\"What dose was confirmed as the recommended phase 2 dose for R/RSCLC?\",\"answer\":\"The optimal RP2D was confirmed as 1.8 mg/kg Q3W for patients with R/RSCLC, based on safety, preliminary efficacy measures, and pharmacokinetics.\"}]","SEZ6-targeting antibody-drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors - a phase 1 trial | PDF",1790104932,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/781f35ada9ee46cdfa73090a64780f70.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/389f5717d01c3a1d7cf2dcdab6b33d70.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c82e545fd4f90b1f3d2af7a6003cc6d5.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0752b2f36beccf0c8b92120466d09401.webp",980,1301]